ES3057447T3 - Solid solution compositions for nsaids - Google Patents

Solid solution compositions for nsaids

Info

Publication number
ES3057447T3
ES3057447T3 ES21214529T ES21214529T ES3057447T3 ES 3057447 T3 ES3057447 T3 ES 3057447T3 ES 21214529 T ES21214529 T ES 21214529T ES 21214529 T ES21214529 T ES 21214529T ES 3057447 T3 ES3057447 T3 ES 3057447T3
Authority
ES
Spain
Prior art keywords
weight
peg
approximately
lipid
liquid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21214529T
Other languages
English (en)
Spanish (es)
Inventor
Robin Mark Bannister
John Brew
Richard Robert Reiley
Wilson Caparros-Wanderley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Infirst Healthcare Ltd
Original Assignee
Infirst Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP15180256.8A external-priority patent/EP3127556A1/en
Priority claimed from US14/821,687 external-priority patent/US9744132B2/en
Application filed by Infirst Healthcare Ltd filed Critical Infirst Healthcare Ltd
Application granted granted Critical
Publication of ES3057447T3 publication Critical patent/ES3057447T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES21214529T 2015-08-07 2016-08-08 Solid solution compositions for nsaids Active ES3057447T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15180256.8A EP3127556A1 (en) 2015-08-07 2015-08-07 Solid solution compositions for nsaid
US14/821,687 US9744132B2 (en) 2010-10-29 2015-08-07 Solid solution compositions and use in chronic inflammation

Publications (1)

Publication Number Publication Date
ES3057447T3 true ES3057447T3 (en) 2026-03-02

Family

ID=56800263

Family Applications (2)

Application Number Title Priority Date Filing Date
ES21214529T Active ES3057447T3 (en) 2015-08-07 2016-08-08 Solid solution compositions for nsaids
ES16756963T Active ES2906571T3 (es) 2015-08-07 2016-08-08 Composiciones de soluciones sólidas para AINEs

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES16756963T Active ES2906571T3 (es) 2015-08-07 2016-08-08 Composiciones de soluciones sólidas para AINEs

Country Status (10)

Country Link
EP (2) EP3988091B1 (https=)
JP (1) JP6989489B2 (https=)
CN (1) CN108025078A (https=)
AU (1) AU2016306610B2 (https=)
CA (1) CA2994899C (https=)
ES (2) ES3057447T3 (https=)
IL (1) IL257385A (https=)
MX (1) MX387217B (https=)
PL (1) PL3331568T3 (https=)
WO (1) WO2017025517A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
CA3212583A1 (en) 2021-03-27 2022-10-06 Daniel Gooding Compositions having improved bioavailability of therapeutics

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US10695432B2 (en) * 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9308213B2 (en) * 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
KR102235264B1 (ko) * 2013-01-14 2021-04-02 인퍼스트 헬스케어 리미티드 고용체 조성물들 및 심각한 통증에서의 이들의 용도

Also Published As

Publication number Publication date
AU2016306610B2 (en) 2019-02-28
PL3331568T3 (pl) 2022-02-28
EP3988091A1 (en) 2022-04-27
WO2017025517A1 (en) 2017-02-16
MX2018001584A (es) 2019-01-31
EP3331568B1 (en) 2021-12-15
IL257385A (en) 2018-04-30
MX387217B (es) 2025-03-18
CA2994899A1 (en) 2017-02-16
AU2016306610A1 (en) 2018-03-01
EP3988091B1 (en) 2025-10-01
JP6989489B2 (ja) 2022-01-05
EP3331568A1 (en) 2018-06-13
ES2906571T3 (es) 2022-04-19
CN108025078A (zh) 2018-05-11
EP3988091C0 (en) 2025-10-01
JP2018526351A (ja) 2018-09-13
CA2994899C (en) 2024-04-16

Similar Documents

Publication Publication Date Title
ES3057447T3 (en) Solid solution compositions for nsaids
JP7748411B2 (ja) 固溶体組成物
US20200129461A1 (en) Compositions Comprising Cancer Drug-Fatty Acid Conjugates
US20100099766A1 (en) Topical NSAID compositions having sensate component
US10695431B2 (en) Solid solution compositions and use in cardiovascular disease
US20220040102A1 (en) Solid Solution Compositions and Use in Chronic Inflammation
WO2014117999A1 (en) Compositions and methods for treating chronic inflammation and inflammatory diseases
ES2983643T3 (es) Terapia oral con tridecanoato de testosterona
CA2897874A1 (en) Compositions and methods for treating severe pain
US20200297850A1 (en) Solid Solution Compositions and Use in Cardiovascular Disease
JP2018505905A (ja) 局所医薬製剤
ES2459444T3 (es) Combinación sinérgica de compuestos analgésicos
EP3127556A1 (en) Solid solution compositions for nsaid
ES2333638B2 (es) Uso del acido maslinico para el tratamiento de dolores de naturaleza nociceptiva, inflamatoria y neurogenica.
ES2952013T3 (es) Combinación de ibuprofeno y tramadol para aliviar el dolor
KR20250068718A (ko) 피부 방사선 손상의 예방 및 치료를 위한 조성물 및 방법
ES2692845T3 (es) Composición para aliviar el dolor, el estrés y el insomnio
PT2405892E (pt) Formulação farmacêutica compreendendo cetoprofeno e um éster polioxialquileno de um ácido gordo hidroxilado
HK40018887A (en) Solid solution compositions and use in chronic inflammation
HK40018887B (en) Solid solution compositions and use in chronic inflammation